| Literature DB >> 35612503 |
Alberto Maria Saibene1,2, Fabiana Allevi1,3, Tareck Ayad1,4, Jérome R Lechien1,5, Miguel Mayo-Yáñez1,6,7, Krzysztof Piersiala1,8, Carlos M Chiesa-Estomba1,9.
Abstract
Entities:
Keywords: antibiotics; drainage; parotitis; salivary gland; sialadenitis
Mesh:
Substances:
Year: 2022 PMID: 35612503 PMCID: PMC9132006 DOI: 10.14639/0392-100X-N1837
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.618
Search keys and results for each database consulted.
| Database | Search key | Date of search | No. of items |
|---|---|---|---|
| Medline | ((“parotid gland”[MeSH Terms] OR (“parotid”[All Fields] AND “gland”[All Fields]) OR “parotid gland”[All Fields] OR “parotid”[All Fields] OR “parotids”[All Fields] OR “parotid”[All Fields] OR “parotideal”[All Fields]) AND (“abscess”[MeSH Terms] OR “abscess”[All Fields] OR “abscesses”[All Fields] OR “abscessation”[All Fields] OR “abscessed”[All Fields] OR “abscessing”[All Fields])) OR (“salivary”[All Fields] AND (“abscess”[MeSH Terms] OR “abscess”[All Fields] OR “abscesses”[All Fields] OR “abscessation”[All Fields] OR “abscessed”[All Fields] OR “abscessing”[All Fields])) OR ((“sialadenitis”[MeSH Terms] OR “sialadenitis”[All Fields] OR “sialoadenitis”[All Fields]) AND (“abscess”[MeSH Terms] OR “abscess”[All Fields] OR “abscesses”[All Fields] OR “abscessation”[All Fields] OR “abscessed”[All Fields] OR “abscessing”[All Fields])) | January 18th, 2021 | 581 |
|
| (parotid AND abscess) OR (salivary AND abscess) OR (sialoadenitis AND abscess) | 5 | |
| Cochrane Library | (parotid AND abscess) OR (salivary AND abscess) OR (sialoadenitis AND abscess) in All Text - (Word variations have been searched) | 16 | |
| Web of Science | ALL FIELDS: ((parotid AND abscess) OR (salivary AND abscess) OR (sialoadenitis AND abscess)) | 338 | |
| Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC. | |||
| Embase | parotid AND (‘abscess’/exp OR abscess) OR (salivary AND (‘abscess’/exp OR abscess)) OR ((‘sialoadenitis’/exp OR sialoadenitis) AND (‘abscess’/exp OR abscess)) | 987 |
Figure 1.PRISMA flow diagram of study selection through systematic review.
Figure 2.Geographical representation of the countries of origin of the reviewed articles (in green: one article only; in blue: two or more articles).
Characteristics of the included studies.
| Study type | OCEBM rating | NHI-SQAT score | NHI-SQAT rating | Country | Treated patients (n) | Male to female ratio (n) | Patient age (years) | Specific patient subgroup studied | |
|---|---|---|---|---|---|---|---|---|---|
| Cheng et al., 2019 [ | CS | 4 | 8/9 | G | Taiwan | 19 | 12 M : 7 F | Mean 55.5, range 25-88 | None |
| Chi et al., 2014 [ | CS | 4 | 7/9 | F | Taiwan | 14 | 9 M : 5 F | Mean 49.6, SD 14.4, range 22-75 | None |
| Cmejrek et al., 2002 [ | CS | 4 | 5/9 | F | US | 1 | UNS | UNS | Age < 9 mo |
| Daramola et al., 2009 [ | CS | 4 | 6/9 | f | US | 3 | 3 F | 0.17; 0.33; 7 | None |
| de la Cuesta et al., 2018 [ | CS | 4 | 5/9 | F | Spain | 4 | UNS | Mean 2.4, SD 2.4 | Aged < 15 y |
| Franklyn et al., 2016 [ | CS | 4 | 6/9 | F | India | 40 | 28 M : 12 F | Mean 46.8, SD 15.8, median 44 | None |
| Ganesh and Leese, 2005 [ | CS | 4 | 7/9 | F | Singapore | 10 | 3 M : 7 F | Median 37, range 20-84 | None |
| Jaboñska-Jesionowska et al., 2017 [ | CS | 4 | 5/9 | F | Poland | 2 | UNS | UNS | Paediatric patients |
| Joo et al, 2017 [ | PCS | 2 | F | South Korea | 4 | UNS | UNS | None | |
| Kim et al., 2018 [ | CS | 4 | 8/9 | G | South Korea | 13 | 11 M : 2 F | Mean 51, SD 24.3, range 7-80 | None |
| Lakshmi Narayana et al., 2015 [ | CS | 4 | 8/9 | F | India | 7 | 6 M : 1 F | Range 0.67-15 | Paediatric patients |
| Laskawi et al., 2005 [ | CS | 4 | 5/9 | F | Germany | 5 | UNS | UNS | Paediatric patients |
| Mahawerawat and Kasemsiri, 2018 [ | CS | 4 | 6/9 | F | Thailand | 22 | UNS | UNS | Melioidosis cases |
| Nusem-Horowitz, 1995 [ | CS | 4 | 4/9 | P | Israel | 4 | UNS | UNS | Paediatric patients |
| Saarinen et al., 2007 [ | CS | 4 | 8/9 | G | Finland | 10 | 5 M : 5 F | Median 10, range 2.2-16.8 | Age <17 y |
| Stong et al., 2005 [ | CS | 4 | 5/9 | F | US | 2 | UNS | Mean 6.5, range 0.5-15 | Paediatric patients |
| Tan and Goh, 2006 [ | CS | 4 | 8/9 | G | Malaysia | 15 | 10 M : 5 F | Median 51, range 0.92-77 | None |
| Thiede et al., 2002 [ | CS | 4 | 8/9 | G | Germany | 36 | 15 M : 21 F | Median 44, range 3 mo-79 y | None |
OCEBM: Oxford Centre for Evidence-Based Medicine; NHI-SQAT: National Heart, Lung, and Blood Institute Study Quality Assessment Tools; CS: case series; PCS: prospective cohort study; F: fair; G: good; P: poor; US: United States of America; M: male; F: female; UNS: unspecified; SD: standard deviation; mo: months. y: years.
Diagnostic modalities, treatment arms, and outcomes for reviewed studies.
| Abscess diagnostic modalities | Treatment arms | Antibiotic treatment | Outcome | Other complications | |
|---|---|---|---|---|---|
| Cheng et al., 2019 [ | CT (n = 19) | ABx + I&D (n = 14) | Amoxicillin/clavulanate (n = 11), or clindamycin (n = 8) first, antibiogram driven next | 14/14 cured | None |
| ABx + US-guided aspiration (n = 4) | 4/4 cured | ||||
| ABx (n = 1) | 1/1 died | ||||
| Chi et al., 2014 [ | CT (n = 14) | ABx + I&D (n = 14) | UNS broad-spectrum ABx | 14/14 cured | Salivary fistula (n = 1) |
| Cmejrek et al., 2002 [ | UNS | ABx + I&D (n = 1) | UNS empirical ABx first, antibiogram-driven next | 1/1 cured | None |
| Daramola et al., 2009 [ | CT (n = 3) | ABx + I&D (n = 2) | UNS empirical ABx first, antibiogram-driven next | 2/2 cured | None reported |
| ABx (n = 1) | 1/1 cured | ||||
| de la Cuesta et al., 2018 [ | UNS | ABx + I&D (n = 4) | UNS ABx | 2/4 cured, 2/4 required another I&D | None |
| Franklyn et al., 2016 [ | US (n = 17), CT+MRI (n=14), clinical (n = 9) | ABx + I&D (n = 30) | Cloxacillin and metronidazole first, antibiogram-driven next | 26/30 cured, 4/30 required another I&D | None |
| ABx + unguided aspiration (n 5) | 2/5 cured, 3/5 required I&D | ||||
| ABx in spontaneous rupture (n = 1) | 1/1 cured | ||||
| ABx (n = 3) | 3/3 cured | ||||
| no therapy (n = 1) | 1/1 died | ||||
| Ganesh and Leese, 2005 [ | CT (n = 9), clinical (n = 1) | ABx + I&D (n = 8) | UNS ABx (most frequently ceftriaxone) | 7/8 cured, 1 required another I&D | None |
| ABx in spontaneous rupture (n = 1) | 1/1 cured | ||||
| ABx + CT-guided aspiration (n = 1) | 1/1 cured | ||||
| Jaboñska-Jesionowska et al., 2017 [ | UNS | ABx + I&D (n = 2) | Amoxiclavulanate or cephalosporin with clindamycin | 2/2 cured | None |
| Joo et al., 2017 [ | CT + US (n = 4) | ABx + US-guided aspiration (n = 4) | UNS ABx | 4/4 cured | None |
| Kim et al., 2018 [ | CT (n = 13) | ABx + I&D (n = 7) | UNS broad-spectrum ABx | 6/7 cured, 1/7 required another I&D | None |
| ABx (n = 6) | 6/6 cured | ||||
| Lakshmi Narayana et al., 2015 [ | US (n = 3), clinical (n = 4) | ABx + I&D (n = 7) | Amoxiclavulanate, changed to clindamycin due to lack of response in 2 patients | 7/7 cured | Temporary marginal branch palsies (n = 2) |
| Laskawi et al., 2005 [ | UNS | ABx + I&D (n = 5) | Amoxicillin and/or flucloxacillin | 5/5 cured | None |
| Mahawerawat and Kasemsiri, 2018 [ | UNS | ABx + I&D (n = 22) | Ceftazidime followed by co-trimoxazole (either with or without doxycycline) or amoxi-clavulanate | 21/22 cured, 1/22 died | None |
| Nusem-Horowitz, 1995 [ | US (n = 2), US after recurrence (n = 1), clinical (n = 1) | ABx + I&D (n = 4) | Penicillin G and cloxacillin | 3/4 healed, 1/4 required another I&D | None |
| Saarinen et al., 2007 [ | US (n = 9), MRI (n = 1) | ABx+ I&D (n = 3) | UNS broad-spectrum ABx (in most cases metronidazole with penicillin or cefuroxime; clindamycin in one case) | 3/3 cured | None |
| ABx + US-guided aspiration (n = 4) | 2/4 cured, 2/4 required I&D | None | |||
| ABx in spontaneous rupture (n = 3) | 2/3 cured, 1/3 required targeted therapy (mycobacteriosis) | Salivary fistula (n = 2) | |||
| Stong et al., 2005 [ | CT (n = 2) | ABx + I&D (n = 2) | UNS ABx | 2/2 cured | None |
| Tan and Goh, 2006 [ | US (n = 5), CT (n = 8), clinical (n = 2) | ABx+ I&D (n = 15, in one case with underlying tumour resection) | IV cephalosporins (n=7) IV ampicillin/clavulanate (n=8), concurrent IV metronidazole (n=10). Changed to antibiogram driven when indicated | 12/15 cured, 2/15 died, 1/15 required another I&D | 1 definitive facial paralysis following re-exploration, 2 wounds with difficult healing |
| Thiede et al., 2002 [ | US (n = 34), US+CT (n=2), MRI in selected (n=?) | ABx + I&D (n = 36) | Amoxiclavulanate unless already prescribed prior to I&D | 35/36 cured, 1/36 required parotidectomy | Temporary marginal branch palsies (n=1) |
CT: computed tomography; UNS: unspecified; US: ultrasound; MRI: magnetic resonance imaging; Abx: antibiotics; I&D: incision and drainage.
Microbiological results (where available) for the included studies.
| Culture yield | |
|---|---|
| Cheng et al., 2019 [ | No yield (n = 6), K. pneumoniae (n = 6), S. aureus (n = 2), H. influenzae (n = 1), P. micros (n = 1), M. tuberculosis (n = 1), Candida parapsilosis (n = 1), Salmonella Group D (n = 1) |
| Chi et al., 2014 [ | No yield (n = 6), K. pneumoniae (n = 4), F. magna (n = 1), H. influenzae (n = 1), S. aureus (n = 2) |
| Franklyn et al., 2016 [ | No yield (n = 3), S. aureus (n = 10), Klebisiella spp. (n = 6), B-haemolytic Streptococcus spp. (n = 4), non-haemolytic Streptococcus spp. (n = ), Enterococcus spp (n = 2), Proteus spp. (n = 1), E. coli (n = 1), Enterobacter spp. (n = 1), M. tuberculosis (n = 2) |
| Ganesh and Leese, 2005 [ | No yield (n = 5), S. aureus (n = 2), K. pneumoniae (n = 1), E. coli (n = 1), A-haemolytic Streptococcus spp. (n = 1) |
| Jaboñska-Jesionowska et al., 2017 [ | S. aureus (n = 2) |
| Kim et al., 2018 [ | No yield (n = 5), P. aeruginosa (n = 1), P. intermedia (n = 1), S. epidermidis (n = 1); P. acnes (n = 1) |
| Lakshmi Narayana et al., 2015 [ | No yield (n = 2), MSSA (n = 3), B-Haemolytic Streptococcus spp. (n = 1), E. coli (n = 1) |
| Laskawi et al, 2005 [ | S. aureus (n = 5) |
| Mahawerawat and Kasemsiri, 2018 [ | B. pseudomallei (n = 22) |
| Nusem-Horowitz, 1995 [ | No yield (n = 1), Gram-negative cocci (n = 1), coagulase negative Staphylococci (n = 1), anaerobic Streptococci (n = 1) |
| Saarinen et al., 2007 [ | No yield (n=3), H. Influenzae (n = 3), S. pneumoniae (n = 1), P. mirabilis (n = 1), M. tuberculosis (n = 1) |
| Stong et al., 2005 [ | S. Viridans (n = 1), S. aureus (n = 1) |
| Tan and Goh, 2006 [ | No yield (n = 5), S. aureus (n = 2), MRSA (n = 1), S. milieri (n = 1), S. pyogenes (n = 1), Klebsiella spp (n = 3), Psuedomonas spp. (n = 1), Haemophilus spp. (n = ١) |
| Thiede et al., 2002 [ | No yield (n = 10), S. aureus (n = 9), S. epidermidis (n = 1), Streptococcu spp. (n = 5), Peptostreptococcus spp. (n = 4), M. tuberculosis (n = 2), atypical mycobacteria (n = 2) |